Literature DB >> 1551991

Comparison of six commercial human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay kits for detection of antibody to HTLV-I and -II.

C Cossen1, S Hagens, R Fukuchi, B Forghani, D Gallo, M Ascher.   

Abstract

Three licensed and three research human T-cell lymphotropic virus type I (HTLV-I) enzyme immunoassay (EIA) kits were evaluated with a panel of 213 serum or plasma samples which were previously tested by the indirect immunofluorescence method for HTLV-I and -II antibodies. The three research kits were found to be more sensitive and specific than the three licensed kits.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1551991      PMCID： PMC265141          DOI： 10.1128/jcm.30.3.724-725.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  8 in total

1.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

2.  Comparison of Western immunoblot antigens and interpretive criteria for detection of antibody to human T-lymphotropic virus types I and II.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

3.  Evaluation of enzyme immunoassays for antibody to human T-lymphotropic viruses type I/II.

Authors:  R L Kline; T Brothers; N Halsey; R Boulos; M D Lairmore; T C Quinn
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

4.  Comparison of immunofluorescence, enzyme immunoassay, and Western blot (immunoblot) methods for detection of antibody to human T-cell leukemia virus type I.

Authors:  D Gallo; M N Hoffman; C K Cossen; J L Diggs; J W Hurst; L M Penning
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

5.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

6.  High prevalence of HTLV-II among intravenous drug abusers: PCR confirmation and typing.

Authors:  S Kwok; D Gallo; C Hanson; N McKinney; B Poiesz; J J Sninsky
Journal:  AIDS Res Hum Retroviruses       Date:  1990-04       Impact factor: 2.205

7.  Patterns of HIV-1 and HTLV-I/II in intravenous drug abusers from the middle atlantic and central regions of the USA.

Authors:  H H Lee; S H Weiss; L S Brown; D Mildvan; V Shorty; L Saravolatz; A Chu; H M Ginzburg; N Markowitz; D C Des Jarlais
Journal:  J Infect Dis       Date:  1990-08       Impact factor: 5.226

8.  High frequency of human T-cell leukemia-lymphoma virus type II infection in New Mexico blood donors: determination by sequence-specific oligonucleotide hybridization.

Authors:  B Hjelle; R Scalf; S Swenson
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113
  8 in total
  8 in total

1.  The Changing Epidemiology of Human T-Cell Lymphotropic Virus Type 1 Infection in Peruvian Female Sex Workers, 1993-2010.

Authors:  Jenell Stewart; Kristen Heitzinger; Simon Pollett; Martha Calderón; Jorge Alarcón; Thanh G N Ton; Joseph R Zunt
Journal:  Am J Trop Med Hyg       Date:  2016-11-22       Impact factor: 2.345

2.  Sensitivities of radioimmunoprecipitation assay and PCR for detection of human T-lymphotropic type II infection.

Authors:  D Gallo; L M Penning; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

3.  Comparison of four enzyme immunoassays for detection of human T-cell lymphotropic virus type 2 antibodies.

Authors:  D Gallo; E T Yeh; E S Moore; C V Hanson
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

4.  Human T-cell lymphotropic virus type 1 gag indeterminate western blot patterns in Central Africa: relationship to Plasmodium falciparum infection.

Authors:  R Mahieux; P Horal; P Mauclère; O Mercereau-Puijalon; M Guillotte; L Meertens; E Murphy; A Gessain
Journal:  J Clin Microbiol       Date:  2000-11       Impact factor: 5.948

5.  Serological, epidemiological, and molecular differences between human T-cell lymphotropic virus Type 1 (HTLV-1)-seropositive healthy carriers and persons with HTLV-I Gag indeterminate Western blot patterns from the Caribbean.

Authors:  F Rouet; L Meertens; G Courouble; C Herrmann-Storck; R Pabingui; B Chancerel; A Abid; M Strobel; P Mauclere; A Gessain
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Evaluation of an immunoblot assay for serological confirmation and differentiation of human T-cell lymphotropic virus types I and II.

Authors:  B D Roberts; S K Foung; J J Lipka; J E Kaplan; K G Hadlock; G R Reyes; L Chan; W Heneine; R F Khabbaz
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

7.  Evaluation of two commercial human T-cell lymphotropic virus western blot (immunoblot) kits with problem specimens.

Authors:  D Gallo; J L Diggs; C V Hanson
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

8.  Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group.

Authors:  D R Henrard; V Soriano; E Robertson; M Gutierrez; J Stephens; F Dronda; F Miles; E Pujol; M Buytendorp; A Castro
Journal:  J Clin Microbiol       Date:  1995-07       Impact factor: 5.948
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.